Do Genetics Explain Variability in Weight-Loss Response to Liraglutide?

Home » blog » Do Genetics Explain Variability in WeightLoss Response to Liraglutide?

Do Genetics Explain Variability in WeightLoss Response to Liraglutide?

sharma-obesity-dna_molecule9As by any medication (for anything!) not everyone responds the identical.

Now a small study by Mojca Jensterle and colleagues from Ljubljana, published in the European Journal of Clinical Pharmacology, reports that genetic variability in the GLP-1 receptor gene may prognosticate the variability to the human GLP-1 parallel liraglutide, now approved for obesity usage in the US, Canada and Europe.

In their study, Jensterle and colleagues consider the realationship between two common alleles (variants) of the GLP-1 receptor in 57 women through obesity and polycystic ovary syndrome.

All women were treated through liraglutide 1.2 mg QD s.c (well for that which is less than the 3.0 mg QD prescribed portion approved for obesity treatment) for 12 weeks.

Twenty of the participants were classified similar to strong responders (>5% weight deprivation), who lost about 7.4 Kg, it being the case that 37 were considered poor responders losing only 2.2 Kg.

Carriers of at in the smallest degree one rs10305420 allele were about 70% in a ~ degree likely to be a high responder than individuals through two wild-type alleles. Similarly, carriers of at in the smallest degree one rs6923761 allele were about three ages as likely to high responders compared to homozygous carriers of the fanciful type.

Although my previous work in these type of genetic studies have made me in a high degree. critical (not to say sceptical) of these types of weak studies, the notion that genetic variability in the GLP-1 receptor (the molecular target of liraglutide) may well prevail on to differences in response is not entirely that far fetched.

Thus, whether authentic or not, I have little suspense that indeed much of the variability in pharmacological response to liraglutide (or for that difficulty any other drug for anything) may well subsist determined by genetics.

Whether testing nation for genetic markers before starting a particular treatment will ever become reality as far as concerns obesity and whether or not, the genetic variability seen in this study exercise volition still be seen when lirglutide is used at the not imaginary dose approved for obesity treatment remainder to be seen.

In the in the mean time, the easiest way to see who responds and who does not is to try it. This for what cause the regulatory approval of liraglutide on the side of obesity comes with a simple stopping mastery – if it doesn’t operate for you – stop taking it!

Edmonton, Alberta

Disclaimer: I desire received consulting and speaking honoraria from Novo Nordisk, the signer of a promissory note of liraglutide.

VN:F [1.9.22_1171]

please wait…

Rating: 0.0/10 (0 votes found)

VN:F [1.9.22_1171]

Rating: 0 (from 0 votes)

V2 Renal Denervation System conducive to the treatment of drug resistant hypertension is some over the wire balloon catheter with electrodes mounted on the exterior of the balloon to facilitate the delivery of RF inside the renal artery.

Recent Comments